6/29/23, 1:09 AM REDUCE (delirium) Pathway Feedback Search Clinical Topics Home Studies REDUCE (delirium) REDUCE (delirium) Disease ICU delirium Trial question What is the effect of haloperidol among critically ill patients with a high risk of delirium? Study design Multi-center Double blinded RCT Population Characteristics of study participants 38.0% female N = 1439 62.0% male 1439 patients (546 female, 893 male) Inclusion criteria: critically ill adults at high risk of delirium whose ICU stay was at least a day Key exclusion criteria: delirium prior to inclusion; Parkinson's disease, history of acute neurological conditions; history of psychiatric disease and use of antipsychotic agents; known allergy or intolerance to haloperidol Interventions N=732 haloperidol (2 mg intravenous infusion TID) N=707 placebo (intravenous infusion of 0.9% sodium chloride TID) Primary outcome Incidence of delirium at 28 days https://web.pathway.md/studies/rec5mxH2RbaYZXaKU 1/2 6/29/23, 1:09 AM REDUCE (delirium) Pathway 33.3 % 33.3 33 25.0 % 16.6 % 8.3 % No significant difference 0.0 % Haloperidol Placebo No significant difference in incidence of delirium at 28 days (33.3% vs. 33%; AD 0.4%, 95% CI -4.6 to 5.4) Safety outcomes No significant difference in reported adverse events. Conclusion In critically ill adults at high risk of delirium whose ICU stay was at least a day, haloperidol was not superior to placebo with respect to incidence of delirium at 28 days. Reference Mark van den Boogaard, Arjen J C Slooter, Roger J M Br ggemann et al. Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. JAMA. 2018 Feb 20;319(7):680-690. Open reference URL https://web.pathway.md/studies/rec5mxH2RbaYZXaKU 2/2